CTRI/2009/091/000654已完成2 期
A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients With Treatment-Resistant Depression
Eli Lilly and Company India Pvt Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Have recurrent unipolar MDD, without psychotic features by DSMIV- TR clinical assessment, confirmed by the structured clinician Interview for DSM-IV Acis 1 disorders
- •-If female and of childbearing potential, test negative for pregnancy and agree to abstain from sexual activity or use a medically accepted means of contraception during the study. Use of any oral or injectable contraception must be initiated prior to receiving treatment.
- •-Have 17-item HAM-D score greater than or equal to 18 at screening and the day treatment is due to be received for the first time.
- •-Have treatment-resistant depression, as defined by having demonstrated failure to achieve satisfactory antidepressant response to adequate separate treatment courses of at least 2 different antidepressants within the current episode of MDD.
排除标准
- •-Have a diagnosis of Parkinson's disease or related disorders.
- •-Have a current or lifetime diagnosis of any of the following according to DSM-IV criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Psychotic Disorder Not Otherwise Specified, Bipolar Disorder I or II, Delirium of any type, Dementia of any type, Amnestic Disorder, any Substance-Induced Disorder, or any Psychotic Disorder due to a General Medical Condition.
- •-Have current diagnosis of post-partum depression, MDD with atypical features, or MDD with a seasonal pattern as defined in the DSM-IV.
- •-Have paranoid, schizoid, schizotypal, antisocial, and borderline personality disorders (Axis II) as a comorbid or primary diagnosis, based on DSM-IV criteria.
- •-Have had psychotic symptoms within 1 month prior to Screening or demonstrate psychotic features at screening and on the day treatment is due to be assigned for the first time as determined by the investigator.
- •-Have DSM-IV substance dependence/abuse or not willing to avoid use of the substance (not including dependence on nicotine or caffeine), as defined by the SCID-I, within the past 30 days.
- •-Are actively suicidal in the judgment of the investigator.
- •-Have had one or more seizures without a clear and resolved etiology.
- •-Have leukopenia or history of leukopenia without a clear and resolved etiology, or known history of agranulocytosis during the patient's lifetime.
- •-Have ALT/SGPT values greater than or equal to 2 times the upper limit of normal of the performing laboratory (ULN) or AST/SGOT values greater than or equal to 2 times the ULN or total bilirubin values greater than or equal to 1.5 times the ULN at screening.
- •-Have acute, serious, or unstable medical conditions
- •-Have any illness such that death is anticipated within 1 year or intensive care unit hospitalization for the illness is anticipated within 6 months.
- •-Have elevated prolactin levels at screening.
- •-Have QTc Bazett's >450 milliseconds (male) or >470 milliseconds (female) at screening and when treatment is due to be received for the first time.
- •-Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) treatment within the current episode; have a history of failure to adequate treatment courses of ECT or VNS; or will require ECT or VNS at any time during study participation.
- •If receiving psychotherapy, light therapy, or both, are anticipated to require changes in frequency/intensity of treatment regimen or to cease treatment regimen over the duration of the study. Patients who are not receiving any of these therapies upon study entry may not begin any of these therapies during screening, or during any treatment phases of the study.
- •-Have received previous treatment with clozapine.
- •-Have used a monoamine oxidase inhibitor (MAOI) within 14 days prior to screening or are expected to need MAOI treatment at any time during this study through 5 weeks after the patient discontinues from the study
研究者
相似试验
招募中
1 期
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioPulmonary arterial hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code: 10077731Term: Pulmonary hypertension WHO functional class I Class: 10038738CTIS2023-509305-68-00nited Therapeutics Corp.633
进行中（未招募）
1 期
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioEUCTR2018-001189-40-BEnited Therapeutics Corporation1,000
进行中（未招募）
1 期
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioEUCTR2018-001189-40-HRnited Therapeutics Corporation1,000
进行中（未招募）
1 期
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioPulmonary arterial hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077731Term: Pulmonary hypertension WHO functional class ISystem Organ Class: 100000004855EUCTR2018-001189-40-PTnited Therapeutics Corporation1,000
进行中（未招募）
1 期
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioPulmonary arterial hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077731Term: Pulmonary hypertension WHO functional class ISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-001189-40-DKnited Therapeutics Corporation1,000